HRP20201893T1 - Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura - Google Patents

Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura Download PDF

Info

Publication number
HRP20201893T1
HRP20201893T1 HRP20201893TT HRP20201893T HRP20201893T1 HR P20201893 T1 HRP20201893 T1 HR P20201893T1 HR P20201893T T HRP20201893T T HR P20201893TT HR P20201893 T HRP20201893 T HR P20201893T HR P20201893 T1 HRP20201893 T1 HR P20201893T1
Authority
HR
Croatia
Prior art keywords
pharmaceutical preparation
formula
aliphatic
use according
image
Prior art date
Application number
HRP20201893TT
Other languages
English (en)
Croatian (hr)
Inventor
Scott J. Weir
Shrikant Anant
Original Assignee
The University Of Kansas
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The University Of Kansas filed Critical The University Of Kansas
Publication of HRP20201893T1 publication Critical patent/HRP20201893T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
    • A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
HRP20201893TT 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura HRP20201893T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201462078069P 2014-11-11 2014-11-11
US201562134747P 2015-03-18 2015-03-18
EP15859268.3A EP3217980B1 (en) 2014-11-11 2015-11-10 Ciclopirox, ciclopirox olamine, or a ciclopirox prodrug for use in the treatment of bladder cancer
PCT/US2015/059955 WO2016077346A1 (en) 2014-11-11 2015-11-10 Methods of bladder cancer treatment with ciclopirox, ciclopirox olamine, or a ciclopirox prodrug

Publications (1)

Publication Number Publication Date
HRP20201893T1 true HRP20201893T1 (hr) 2021-02-05

Family

ID=55954945

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20201893TT HRP20201893T1 (hr) 2014-11-11 2015-11-10 Ciklopiroks, ciklopiroks olamin ili ciklopiroks predlijek za uporabu u liječenju raka mokraćnog mjehura

Country Status (12)

Country Link
US (1) US20170304329A1 (enExample)
EP (1) EP3217980B1 (enExample)
JP (1) JP2017533952A (enExample)
CN (2) CN116687941A (enExample)
DK (1) DK3217980T3 (enExample)
ES (1) ES2836208T3 (enExample)
HR (1) HRP20201893T1 (enExample)
HU (1) HUE052670T2 (enExample)
PL (1) PL3217980T3 (enExample)
PT (1) PT3217980T (enExample)
RS (1) RS61222B1 (enExample)
WO (1) WO2016077346A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11753379B2 (en) 2018-05-30 2023-09-12 Clariant International Ltd Process for forming 2-hydroxypyridine-1-oxide or derivatives thereof
CN113194945B (zh) * 2018-08-23 2024-07-23 佩勒梅德有限公司 环吡酮的抑制hbv核心组装的用途
WO2021078937A1 (en) * 2019-10-25 2021-04-29 Deutsches Krebsforschungszentrum Treatment of stat3 related diseases by iron chelators
EP4193989A1 (en) 2021-12-09 2023-06-14 Atlas Molecular Pharma, S.L. A formulation for an effective oral administration of ciclopirox with no adversal gasterointestinal toxicity

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754965B2 (en) 1997-12-31 2002-11-28 University Of Kansas, The Water soluble prodrugs of tertiary amine containing drugs and methods of making thereof
AU2003251875A1 (en) * 2002-07-15 2004-02-02 Combinatorx, Incorporated Combination therapy for the treatment of neoplasms
WO2010048712A1 (en) 2008-10-31 2010-05-06 University Health Network Ciclopirox and cytarabine for the treatment of leukemic disorders
WO2011153197A1 (en) * 2010-06-01 2011-12-08 Biotheryx, Inc. Hydroxypyridone derivatives, pharmaceutical compositions thereof, and their therapeutic use for treating proliferative diseases
PL2646035T3 (pl) * 2010-12-02 2016-08-31 Univ Kansas Proleki 6-cykloheksylo-1-hydroksy-4-metylopirydyn-2(1h)-onu i ich pochodne

Also Published As

Publication number Publication date
DK3217980T3 (da) 2020-12-07
EP3217980A4 (en) 2018-05-02
RS61222B1 (sr) 2021-01-29
ES2836208T3 (es) 2021-06-24
HUE052670T2 (hu) 2021-05-28
US20170304329A1 (en) 2017-10-26
WO2016077346A1 (en) 2016-05-19
CN107206012A (zh) 2017-09-26
JP2017533952A (ja) 2017-11-16
CN116687941A (zh) 2023-09-05
EP3217980B1 (en) 2020-10-14
PL3217980T3 (pl) 2021-03-22
EP3217980A1 (en) 2017-09-20
PT3217980T (pt) 2020-12-11

Similar Documents

Publication Publication Date Title
PH12020551691A1 (en) Solid compositions comprising a glp-1 agonist and a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid
HRP20201681T1 (hr) Inhibitor aurora a kinaze
WO2017180917A3 (en) Lipid compositions and their uses for intratumoral polynucleotide delivery
MY199638A (en) Solid compositions comprising a glp-1 agonist, a salt of n-(8-(2-hydroxybenzoyl)amino)caprylic acid and a lubricant
HRP20250250T1 (hr) Derivati 7‑benzil‑4‑(2‑metilbenzil)‑2,4,6,7,8,9‑heksahidroimidazo[1,2‑a]pirido[3,4‑e] pirimidin‑5(1h)‑ona, njihove soli i njihova upotreba u terapiji
PH12019500830A1 (en) 6,7,8,9-tetrahydro-3h-pyrazolo[4,3-f]isoquinoline derivatives useful in the treatment of cancer
CU20190018A7 (es) Compuestos inhibidores de los receptores endosomales tipo peaje
BR112015007061A8 (pt) composto, composição farmacêutica e uso do composto
NZ712270A (en) Pharmaceutical composition of s-ketamine hydrochloride
HRP20200889T1 (hr) Upotreba dugodjelujućih peptida glp-1
EA201590518A1 (ru) Стабильные водные составы адалимумаба
EA201990388A1 (ru) Пиперидиновые модуляторы рецепторов cxcr7
HRP20210299T1 (hr) Inhibitori histonske demetilaze
WO2016145234A3 (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
BR112016020181A8 (pt) composições de ácido lipoico éster colina e métodos de uso.
EA201401082A1 (ru) Фармацевтические препараты, содержащие антагонисты ccr3
HK1249504A1 (zh) 用作溴结构域抑制剂的吡啶酮二甲酰胺
BR112017002190A2 (pt) derivados de di-hidropteridinona e usos dos mesmos
EA201992679A1 (ru) N-замещенные индольные производные
HRP20221230T1 (hr) Farmaceutske kombinacije koje sadrže inhibitor histon deacetilaze i inhibitor bcl-2 i postupci za njihovu uporabu
HRP20240166T1 (hr) Postupak liječenja prader-willijevog sindroma
RU2019119405A (ru) Лиофилизированные фармацевтические композиции далбаванцина
BR112019000897A2 (pt) sal de adição de ácido, composição farmacêutica, uso do sal de adição de ácido ou da composição farmacêutica, e, método para prevenção, tratamento ou atenuação de um distúrbio de fibrose de tecido ou órgão.
BR112018012458A2 (pt) ?composições farmacêuticas que compreendem o derivado da fenilaminopirimidina?
EA201790179A1 (ru) [1,2,4]триазоло[4,3-b]пиридазины для применения в лечении пролиферативных заболеваний